Table 3 Demographic characteristics and comorbidity status of the Matched hdPS Sub-Cohort at baseline
Low potency n (%) | High potency n (%) | Absolute standardized differences | |
|---|---|---|---|
116,014 (100.0) | 116,014 (100.0) | ||
Age, mean (SD)a | 64.6 (11.2) | 64.6 (11.2) | 0.002 |
Male sex | 58,194 (50.2) | 58,494 (50.4) | 0.005 |
At least 5 medical outpatient visits | 66,453 (57.3) | 66,390 (57.2) | 0.001 |
At least 1 hospitalisation | 28,265 (24.4) | 28,604 (24.7) | 0.007 |
Myocardial infarction | 7558 (6.5) | 7995 (6.9) | 0.015 |
Stroke | 3620 (3.1) | 3897 (3.4) | 0.013 |
Hypertension | 48,268 (41.6) | 48,474 (41.8) | 0.004 |
Hypercholesterolemia | 37,486 (32.3) | 37,841 (32.6) | 0.007 |
Peripheral vascular disease | 2293 (2.0) | 2671 (2.3) | 0.023 |
Congestive heart failure | 5198 (4.5) | 5479 (4.7) | 0.012 |
Coronary artery bypass graft | 1670 (1.4) | 1661 (1.4) | 0.001 |
Percutaneous coronary intervention | 4590 (4.0) | 4846 (4.2) | 0.011 |
Dispensation of loop diuretics | 7139 (6.2) | 7256 (6.3) | 0.004 |
Dispensation of calcium blockers | 26,510 (22.9) | 26,716 (23.0) | 0.004 |
Dispensation of beta-blockers | 33,901 (29.2) | 34,389 (29.6) | 0.009 |
Dispensation of angiotensin receptor blockers | 20,345 (17.5) | 20,876 (18.0) | 0.012 |
Dispensation of angiotensin converting enzyme inhibitors | 24,472 (21.1) | 25,289 (21.8) | 0.017 |
At least 5 different drugs dispensed | 66,600 (57.4) | 66,820 (57.6) | 0.004 |